Anti-hIL6R-To-hIgG1NQ
-
Cat.code:
hil6rto-mab12
- Documents
ABOUT
Anti-IL-6R antibody - Human non-glycosylated IgG1 (low effector functions)
Anti-hIL-6R-hIgG1NQ is a Tocilizumab-based research antibody. Tocilizumab (RG-1569, rhPM-1), also known as TCZ, is a recombinant, humanized IgG1κ monoclonal antibody (mAb) directed against both soluble and membrane-bound human interleukin-6 receptor (IL-6R). Tocilizumab is FDA-approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome.
Anti-hIL-6R-hIgG1NQ comprises the variable region of Tocilizumab fused to a mutated non-glycosylated (NQ) IgG1 constant region with low effector functions. For applications requiring high Fc effector activity, InvivoGen also offer Anti-hIL6R-To-hIgG1, the biosimilar reseach mAb to Tocilizumab.
This antibody can be used with HEK-Blue™ IL-6 cells for screening and neutralization assays to block recombinant human IL-6-induced signaling (see figure).
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect™ assay
In the constant region, the asparagine (N) glycosylation sites were replaced by glutamine (Q) residues, resulting in the production of a non-glycosylated antibody. Glycosylation of an antibody does not affect antigen binding but is essential for Fc receptor-mediated activity [1]. In non-glycosylated antibodies, the effector mechanisms mediated by the Fc receptor types (FcgRI, FcgRII, FcgRIII) and the C1q component of the complement system are severely impaired or switched off [2].
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Interleukin 6 receptor (IL-6R)
Human
0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
< 5%
Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and TLR4 cellular assays.
Negative (tested using EndotoxDetect™ assay)
Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL6R-To-hIgG1NQ
-
Cat code:hil6rto-mab12
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
IL-6R background
Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6 to its receptor [3]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [4]. TCZ can block both modes of signaling [3]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [5].
References:
1. Arnold J. et al., 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50.
2. Jefferis R., 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 8(3):226-34.
3. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
4. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
5. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz